ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...
Nivolumab plus ipilimumab shows promising real-world effectiveness in intermediate- or poor-risk mRCC, with median overall survival of 38.4 months and progression-free survival of 11.1 months.
Adding docetaxel to standard treatment can prolong prostate cancer-specific survival in patients with nonmetastatic prostate cancer with specific features. Adding docetaxel to standard treatment can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback